Ultimovacs ASA
OSE:ULTI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ultimovacs ASA
Interest Income Expense
Ultimovacs ASA
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
U
|
Ultimovacs ASA
OSE:ULTI
|
Interest Income Expense
kr11m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
Interest Income Expense
kr2.1m
|
CAGR 3-Years
74%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
Interest Income Expense
kr9.4m
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
Interest Income Expense
$13.2m
|
CAGR 3-Years
79%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
C
|
Circio Holding ASA
OSE:CRNA
|
Interest Income Expense
-kr104k
|
CAGR 3-Years
60%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
T
|
Thor Medical ASA
OSE:TRMED
|
Interest Income Expense
kr7.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
Ultimovacs ASA
Glance View
Ultimovacs AS operates as a pharmaceutical company. The company is headquartered in Oslo, Oslo. The company went IPO on 2019-06-03. The firm's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The firm is performing a broad clinical development program with clinical trials in Europe and the USA.
See Also
What is Ultimovacs ASA's Interest Income Expense?
Interest Income Expense
11m
NOK
Based on the financial report for Dec 31, 2024, Ultimovacs ASA's Interest Income Expense amounts to 11m NOK.
What is Ultimovacs ASA's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
16%
Over the last year, the Interest Income Expense growth was -59%.
